Cat. No.: HY-N0779A

Silybin

(Synonyms: Silibinin)

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity.

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 802918-57-6
Formula: C₂₅H₂₂O₁₀
Molecular Weight:482.44

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Silybin Chemical Structure

CAS No.: 802918-57-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Silybin is a flavonolignan isolated from milk thistle (Silybum marianum) seeds. Silybin induces apoptosis and exhibits hepatoprotective, antioxidant, anti-inflammatory, anti-cancer activity^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	EC₅₀	>10 μM Compound: 1	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay	[PMID: 29407994]
DU-145	IC₅₀	93.34 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26748997]
DU-145	IC₅₀	93.34 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 3 days by WST-1 assay	[PMID: 27261177]
DU-145	IC₅₀	93.34 μM Compound: Silybin	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 28756013]
HCT-116	IC₅₀	50 μM Compound: 53	Anticancer activity against human HCT-116 cells assessed as decrease in cell growth incubated for 72 hrs by tryphan blue staining based cell counter analysis Anticancer activity against human HCT-116 cells assessed as decrease in cell growth incubated for 72 hrs by tryphan blue staining based cell counter analysis	[PMID: 33445154]
Hepatocyte	IC₅₀	15 μM Compound: Silybin	Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine/TNFalpha-induced cytotoxicity after 20 hrs by MTT assay relative to untreated control	[PMID: 19775895]
Hepatocyte	IC₅₀	29.9 μM Compound: silibinin	Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in primary cultured mouse hepatocytes treated for 30 mins before TNFalpha challenge measured after 18 hrs by MTT assay	[PMID: 11277757]
Hepatocyte	IC₅₀	38.8 μM Compound: Silybin	Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
Hepatocyte	IC₅₀	41 μM Compound: silybin	Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay relative to control Hepatoprotective activity in ddY mouse hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay relative to control	[PMID: 15104485]
Hepatocyte	IC₅₀	82.4 μM Compound: silibinin	Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs	[PMID: 11325227]
HepG2	EC₅₀	45 μM Compound: Silybinin	Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay	[PMID: 21459003]
HepG2	EC₅₀	75.7 μM Compound: Silybin	Hepatoprotective activity against nitrofurantoin-induced cytotoxicity in human HepG2 cells after 2 hrs by MTT assay Hepatoprotective activity against nitrofurantoin-induced cytotoxicity in human HepG2 cells after 2 hrs by MTT assay	[PMID: 19489592]
HSC-T6	EC₅₀	18.83 μM Compound: Silybinin	Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay	[PMID: 21459003]
HT-1080	IC₅₀	400 μM Compound: silibinin	Cytotoxicity against human HT1080 cells Cytotoxicity against human HT1080 cells	[PMID: 23953690]
HT-22	EC₅₀	>10 μM Compound: 1	Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay	[PMID: 29407994]
Huh7.5.1	CC₅₀	80 μM Compound: 2	Cytotoxicity against human Huh7.5.1 cells after 72 hrs by ATPlite assay Cytotoxicity against human Huh7.5.1 cells after 72 hrs by ATPlite assay	[PMID: 30485098]
HUVEC	IC₅₀	72.58 μM Compound: 1, silymarin, diastereomericmixture of A and B	Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay Cytotoxicity against HUVEC assessed as cell viability after 16 hrs by MTT assay	[PMID: 21928794]
HUVEC	IC₅₀	9.99 μM Compound: 1, silymarin, diastereomericmixture of A and B	Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay Antiproliferative activity against HUVEC assessed as inhibition of cell growth after 3 days by MTT assay	[PMID: 21928794]
L929	IC₅₀	60.4 μg/mL Compound: Silybin	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
LNCaP	IC₅₀	43.03 μM Compound: 1	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26748997]
LNCaP	IC₅₀	43.03 μM Compound: 1	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 3 days by WST-1 assay	[PMID: 27261177]
LNCaP	IC₅₀	43.73 μM Compound: Silybin	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 28756013]
MDCK	CC₅₀	>800 μM Compound: 1	Cytotoxicity against MDCK cells after 2 hrs by MTT assay Cytotoxicity against MDCK cells after 2 hrs by MTT assay	[PMID: 20036447]
PC-3	IC₅₀	72.65 μM Compound: 1	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26748997]
PC-3	IC₅₀	72.65 μM Compound: 1	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 3 days by WST-1 assay	[PMID: 27261177]
PC-3	IC₅₀	72.65 μM Compound: Silybin	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 28756013]
Rat1	IC₅₀	162 μM Compound: 1, diastereomeric mixture	Cytotoxicity against rat immortalized Rat1 cells after 48 hrs by MTT assay Cytotoxicity against rat immortalized Rat1 cells after 48 hrs by MTT assay	[PMID: 21737270]
RAW264.7	IC₅₀	69.2 μM Compound: Silybin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA	[PMID: 27765508]
SW480	IC₅₀	50 μM Compound: 53	Anticancer activity against human SW480 cells assessed as decrease in cell growth incubated for 72 hrs by tryphan blue staining based cell counter analysis Anticancer activity against human SW480 cells assessed as decrease in cell growth incubated for 72 hrs by tryphan blue staining based cell counter analysis	[PMID: 33445154]

In Vitro

Silybin (0-200 mM; for 72 hours) has growth inhibition in a time- and dose-dependent manner^[1].
Silybin (68 μM; for 72 hours) induces apoptosis and increases the cells in G1-phase of ~22%^[1].
Silybin (68 μM; for 72 hours) induces AKT activity inhibition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HepG2 cell growth
Concentration:

0-200 mM
Incubation Time:

For 72 hours
Result:

Had growth inhibition in a time- and dose-dependent manner with an IC₅₀ of 68 μM.

Apoptosis Analysis^[1]

Cell Line:

HepG2 cell growth
Concentration:

68 μM
Incubation Time:

For 72 hours
Result:

Induced apoptosis in a higher number of cells (60%) when compared to untreated cells.

Cell Cycle Analysis^[1]

Cell Line:

HepG2 cell growth
Concentration:

68 μM
Incubation Time:

For 72 hours
Result:

Increased the cells in G1-phase of ~22% and decreased of 47% the cells in S-phase.

Western Blot Analysis^[1]

Cell Line:

HepG2 cell growth
Concentration:

68 μM
Incubation Time:

For 72 hours
Result:

Induced AKT activity inhibition.

In Vivo

Silybin (50, 100 mg/kg/day; given intragastrically for the last 4 weeks) significantly lowers both serum and hepatic lipid accumulation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6J mice (6-8 weeks old) with nonalcoholic fatty liver disease (NAFLD)^[2]
Dosage:

50, 100 mg/kg
Administration:

Given intragastrically; daily; for the last 4 weeks
Result:

Significantly lowered both serum and hepatic lipid accumulation.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 802918-57-6
Appearance Solid
Molecular Weight 482.44
Formula C₂₅H₂₂O₁₀
Color White to off-white
SMILES

O=C1[C@H](O)[C@@H](C2=CC=C(OC(CO)C(C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15
Synonyms

Silibinin
Structure Classification
- Flavonoids
- Flavanonols
- Phenols
- Polyphenols
Initial Source
- Plants
- Compositae
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (10)

All WBIFRT-PCRHistological Imaging/Staining

Sort by:

Journal Impact Factor

Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Chin Med

Senkyunolide I suppresses hepatic stellate cell activation and liver fibrosis by reprogramming VDR-dependent fatty acid metabolism. [Abstract]

2025 Jun 13;20(1):85. PMID: 40514735

Silybin purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Jun 13;20(1):85. [Abstract]

Silybin (SLB: 100 μM). Western blot analysis of α-SMA.

Silybin purchased from MedChemExpress. Usage Cited in: Chin Med. 2025 Jun 13;20(1):85. [Abstract]

Silybin (SLB: 100 μM). Immunofluorescence analysis of α-SMA.
J Ethnopharmacol

Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. [Abstract]

2022 Apr 24:288:114938. PMID: 34999144
Eur J Pharmacol

Polyunsaturated fatty acids drive neutrophil extracellular trap formation in nonalcoholic steatohepatitis. [Abstract]

2023 Apr 15:945:175618. PMID: 36841284
Int J Mol Sci

Dual Targeting of HIF-1α and DLL4 by Isoxanthohumol Potentiates Immune Checkpoint Blockade. [Abstract]

2026 Feb 5;27(3):1576. PMID: 41683994
Sci Rep

Silibinin mitigates AKI-to-CKD transition via MAPK and PI3K/AKT signaling pathways in Ischemia-Reperfusion injury. [Abstract]

2025 Nov 18;15(1):40609. PMID: 41254063

Silybin purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Nov 18;15(1):40609. [Abstract]

Silybin (100 mg/kg). Western blot analysis of protein levels of kidney injury markers (Kim-1, NGAL).

Silybin purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Nov 18;15(1):40609. [Abstract]

Silybin (20µM; 24 h). qRT-PCR was used to analyze the expression of TNF-α, IL-1β, and IL-6 mRNA in each group.

Silybin purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Nov 18;15(1):40609. [Abstract]

Silybin (100 mg/kg). H&E staining of kidney tissues from each group.
Mol Cell Biol

Silybin Improves Acute Kidney Injury by Regulating HDAC6/NF-κB/NLRP3 Signaling to Reduce Inflammation and Ferroptosis. [Abstract]

2025 Dec 8:1-20. PMID: 41358532

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (51.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0728 mL

10.3640 mL

20.7280 mL

5 mM

0.4146 mL

2.0728 mL

4.1456 mL

10 mM

0.2073 mL

1.0364 mL

2.0728 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 10 mg/mL (20.73 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% Tween-80 in Saline

Solubility: 10 mg/mL (20.73 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Silvia Zappavigna, et al. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci. 2019 May 3;20(9):2190. [Content Brief]

[2]. Runbin Sun, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020 Mar;123:109721. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0728 mL	10.3640 mL	20.7280 mL	51.8199 mL
	5 mM	0.4146 mL	2.0728 mL	4.1456 mL	10.3640 mL
	10 mM	0.2073 mL	1.0364 mL	2.0728 mL	5.1820 mL
	15 mM	0.1382 mL	0.6909 mL	1.3819 mL	3.4547 mL
	20 mM	0.1036 mL	0.5182 mL	1.0364 mL	2.5910 mL
	25 mM	0.0829 mL	0.4146 mL	0.8291 mL	2.0728 mL
	30 mM	0.0691 mL	0.3455 mL	0.6909 mL	1.7273 mL
	40 mM	0.0518 mL	0.2591 mL	0.5182 mL	1.2955 mL
	50 mM	0.0415 mL	0.2073 mL	0.4146 mL	1.0364 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Silybin

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Cosmetic Ingredient Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

Publications Citing Use of MedChemExpress (MCE) Silybin

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Silybin

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Cosmetic Ingredient Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

Publications Citing Use of MedChemExpress (MCE) Silybin

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Silybin Related Classifications

HY-N0779A Related Classifications